Levetiracetam
Product Images NDC 43489-122

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43489-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by China Resources Saike Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 01

Chemical structure of levetiracetam, depicting its molecular arrangement with a five-membered lactam ring, ethyl group, hydrogen, and amide side chain attached to a central carbon atom.*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 02

A bar chart comparing the percentage of patients in three groups: Placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 3,000 mg/day. The chart shows an increasing percentage of patients from Placebo to higher Levetiracetam doses, with specific percentages labeled above each bar.*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 03

A bar chart showing the percentage of patients for three groups: Placebo (6.3%, N=111), Levetiracetam 1,000 mg/day (20.8%, N=106), and Levetiracetam 2,000 mg/day (35.2%, N=105). The vertical axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 04

A vertical bar chart comparing the percentage of patients in two groups: Placebo with 14.4% (N=104) and Levetiracetam 3,000 mg/day with 39.4% (N=180). The y-axis represents the percentage of patients from 0% to 45%. The chart highlights a marked difference between the placebo and Levetiracetam treatment groups.*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 05

A bar graph comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The graph shows 19.6% for the Placebo group and 44.6% for the Levetiracetam group on the y-axis labeled '% of Patients.'*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 06

A bar graph comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The graph shows 19.6% for the placebo group and 43.1% for the Levetiracetam group, with the y-axis labeled as % of Patients.*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 07

A bar chart comparing the percentage of patients in two groups: Placebo (45.2%) and Levetiracetam (72.2%). The vertical axis shows the percentage of patients from 0% to 100%. Sample sizes are listed as N=84 for Placebo and N=79 for Levetiracetam.*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 10

Label for Levetiracetam Tablets, USP 500 mg, containing 120 film-coated tablets. The label shows storage instructions to keep between 20° to 25°C, usual dosage advice referencing the package insert, and a caution to dispense in a child-resistant container. Manufactured by China Resources Saike Pharmaceutical Co., Ltd., and for Secan Pharmaceuticals, Inc. The label also includes an NDC number and instructions for the pharmacist to dispense an accompanying Medication Guide to each patient.*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 11

Label for Levetiracetam Tablets USP, 1,000 mg, displaying the product name, strength, and dosage form. The label indicates it contains 60 tablets and includes storage instructions, dosage advisory to see package insert, and a pharmacist dispensing note. Manufacturer is China Resources Saike Pharmaceutical Co., Ltd., with additional information about the packaged drug and a barcode.*

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 Logo

FDA Label Image

C4526f10 F61e 427c Bbea C1ac50394ad7 Logo1

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.